eClinical Technology and Industy News

Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Initial Safety and Efficacy Data for NKTR-255, a Novel IL-15 Agonist, in Combination with Cetuximab in Solid Tumors Presented in Late-Breaking Abstract Session

SAN FRANCISCO, Nov. 12, 2021 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Excerpt from the Press Release:

Initial clinical results were presented from the dose-escalation stage of a Phase 1/2 study of NKTR-255 in combination with cetuximab in a late-breaking abstract presented by Mehmet Altan, MD, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center on Friday, November 12th.  Collaborator presentations of translational data for bempegaldesleukin in combination with nivolumab and bempegaldesleukin in combination with NKTR-262 data were also featured in two poster presentations by Arika S. Feils at the Department of Human Oncology, University of Wisconsin School of Medicine and Public Health and Annah Rolig, PhD, Earle A. Chiles Research Institute, Providence Cancer Institute, respectively, on Friday, November 12th.

“The data presented at this year’s SITC meeting highlight the strength of our cytokine portfolio and in particular the potential of NKTR-255 in the treatment of patients with solid tumors,” said Jonathan Zalevsky, Ph.D., Senior Vice President and Chief Research & Development Officer at Nektar. “We were excited to see early evidence of clinical benefit in the first patients treated in the dose-escalation portion of the study for NKTR-255 in combination with cetuximab which reinforces the promising synergy of IL-15 in combination with an antibody-dependent cellular cytotoxicity agent for the treatment of solid tumors.”

2021 SITC presentations are available for download at

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?